Version 1
: Received: 29 March 2024 / Approved: 29 March 2024 / Online: 1 April 2024 (10:20:44 CEST)
How to cite:
Chen, P.; Chen, Y.; Chen, H.; Liao, T.; Chang, S.; Yeo, K.; Huang, P.; Chen, D. Association of anti-interferon-γ autoantibodies with severe herpes zoster in rheumatoid arthritis patients treated with Janus kinase inhibitors. Preprints2024, 2024031880. https://doi.org/10.20944/preprints202403.1880.v1
Chen, P.; Chen, Y.; Chen, H.; Liao, T.; Chang, S.; Yeo, K.; Huang, P.; Chen, D. Association of anti-interferon-γ autoantibodies with severe herpes zoster in rheumatoid arthritis patients treated with Janus kinase inhibitors. Preprints 2024, 2024031880. https://doi.org/10.20944/preprints202403.1880.v1
Chen, P.; Chen, Y.; Chen, H.; Liao, T.; Chang, S.; Yeo, K.; Huang, P.; Chen, D. Association of anti-interferon-γ autoantibodies with severe herpes zoster in rheumatoid arthritis patients treated with Janus kinase inhibitors. Preprints2024, 2024031880. https://doi.org/10.20944/preprints202403.1880.v1
APA Style
Chen, P., Chen, Y., Chen, H., Liao, T., Chang, S., Yeo, K., Huang, P., & Chen, D. (2024). Association of anti-interferon-γ autoantibodies with severe herpes zoster in rheumatoid arthritis patients treated with Janus kinase inhibitors. Preprints. https://doi.org/10.20944/preprints202403.1880.v1
Chicago/Turabian Style
Chen, P., Po-Hao Huang and Der-Yuan Chen. 2024 "Association of anti-interferon-γ autoantibodies with severe herpes zoster in rheumatoid arthritis patients treated with Janus kinase inhibitors" Preprints. https://doi.org/10.20944/preprints202403.1880.v1
Abstract
Anti-interferon (IFN)-γ autoantibodies are linked to varicella-zoster virus (VZV) infection. Given the elevated risks of herpes zoster (HZ) in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKi), we aimed to examine the relationship between anti-IFN-γ autoantibodies with HZ development in JAKi-treated patients. In twenty-four RA patients with new-onset HZ and forty-two without HZ, serum titers of anti-IFN-γ autoantibodies, plasma levels of IFN-γ, monocyte chemoattractant protein-1 (MCP-1), and IFN-γ inducible protein-10 (IP-10) were measured by ELISA. Significantly lower MCP-1 levels were observed in patients with HZ compared to those without (median, 98.21pg/ml, interquartile range (IQR) 77.63-150.30pg/ml versus 142.3pg/ml, IQR 106.7-175.6pg/ml, p<0.05). There was no significant difference in anti-IFN-γ titers, IFN-γ levels, or IP-10 levels between patients with and without HZ. Three of 24 patients with HZ had severe HZ with multi-dermatomal involvement. Anti-IFN-γ titers were significantly higher in patients with severe HZ than in those with non-severe HZ (median 24.8ng/ml, IQR 21.0-38.2ng/ml versus 10.5ng/ml, IQR 9.9-15.0ng/ml, p<0.005). In conclusion, patients with HZ had significantly lower MCP-1 levels than those without HZ, and patients with severe HZ had significantly higher titers of anti-IFN-γ than those with non-severe HZ. Given small sample size, our results need further validation in future studies.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
